Compare GRMN & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRMN | ALNY |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | Switzerland | United States |
| Employees | N/A | 115 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4B | 42.7B |
| IPO Year | 2000 | 2004 |
| Metric | GRMN | ALNY |
|---|---|---|
| Price | $267.19 | $309.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 28 |
| Target Price | $256.40 | ★ $471.00 |
| AVG Volume (30 Days) | 585.5K | ★ 1.0M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | 17.67 | ★ 206.88 |
| EPS | ★ 8.59 | 2.33 |
| Revenue | ★ $7,245,519,000.00 | $1,037,418,000.00 |
| Revenue This Year | $12.15 | $52.67 |
| Revenue Next Year | $8.69 | $31.48 |
| P/E Ratio | ★ $31.11 | $132.27 |
| Revenue Growth | 15.06 | ★ 22.88 |
| 52 Week Low | $178.74 | $231.76 |
| 52 Week High | $273.32 | $495.55 |
| Indicator | GRMN | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 71.06 | 42.62 |
| Support Level | $228.60 | $306.07 |
| Resistance Level | N/A | $332.08 |
| Average True Range (ATR) | 5.46 | 11.58 |
| MACD | 2.14 | -1.06 |
| Stochastic Oscillator | 86.69 | 12.67 |
Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.